Galapagos delivers second pre-clinical candidate in alliance with GlaxoSmithKline

Galapagos receives €5.2 million in milestone payments

08-Jul-2009 - Belgium

Galapagos NV announced that it has successfully identified a second pre-clinical candidate compound in its osteoarthritis alliance with GlaxoSmithKline (GSK). Galapagos also reached a milestone on another compound in the alliance. Together these milestones trigger payments totaling €5.2 million to Galapagos.

This pre-clinical candidate is a small molecule that meets all the chemical and biological criteria set by GSK for a potential new medicine. The candidate was developed by Galapagos against a novel target discovered with Galapagos' proprietary platform. The molecule is now ready for scale up chemistry and comprehensive safety evaluation, with the goal of entering Phase I clinical research in 2010.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance